GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
Rating: VRX
Neutral $105

Valeant Pharmaceuticals International Inc (NYSE: VRX) rated to Neutral with price target $105 by Susquehanna

Wednesday,  Jan 6, 2016  10:25 AM ET by Lynn Gilbert

Susquehanna rated Valeant Pharmaceuticals
International Inc (NYSE: VRX) to Neutral with price target $105.

Valeant Pharmaceuticals International is a multi-national specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company focuses on the therapeutic areas of dermatology and neurology. Its products are sold through three segments: Specialty Pharmaceuticals, Branded Generics (Europe) and Branded Generics (Latin America). In January 2008, the Company sold its product rights to Three Rivers Pharmaceuticals, LLC. In June 2008, the Company sold its subsidiaries in Argentina and Uruguay. In September 2008, the Company sold its business operations located in Western and Eastern Europe, Middle East and Africa (the WEEMEA business) to Meda AB of Sweden. In October 2008, the Company completed a worldwide License and Collaboration Agreement with Glaxo Group Limited, a wholly owned subsidiary of GlaxoSmithKline plc. In May 2009, the Company acquired EMO-FARM Ltd., a privately held company located in Poland.

Susquehanna



RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy